Analysis of responses showed improved survival in patients with higher inhibitory myeloid signatures receiving VEGF and PD-L1 inhibition, suggesting the combination relieves immune suppression in the tumor microenvironment [23]. The gene discussed is CD274; the disease is neoplasm.